Navigation Links
Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
Date:9/18/2007

e receiving an optimized regimen

alone,

-- that Selzentry along with an optimized background regimen significantly

increased CD4 cells as compared to patients receiving optimized

background regimen alone, and

-- that patients receiving Selzentry experienced similar adverse events to

those receiving an optimized regimen alone.

Monogram's phenotypic resistance tests were used to optimize background therapy in Selzentry's clinical trials.

Selzentry is designed to work differently from other available HIV medications. CCR5 antagonists block the virus from gaining access into healthy cells via the CCR5 co-receptor, a common pathway for viral entry. Monogram's Trofile co-receptor tropism assay identifies whether individual strains of HIV use the CCR5 co-receptor, the CXCR4 co-receptor or both co- receptors to infect healthy cells. This helps clinicians determine whether a CCR5 antagonist like maraviroc may be a good therapeutic option for treating individual patients. Currently available in the U.S., Selzentry is the first drug in a new oral class of HIV medications to be approved in more than ten years. Selzentry (Maraviroc) is under review with European regulatory authorities and recently received a positive opinion from the CHMP.

Selzentry and other entry inhibitors currently in development come at a time when increasing drug resistance makes treating HIV more difficult than ever. Highly sensitive and precise diagnostic tools, such as Trofile, are playing an ever more important role in the development of new therapeutic approaches that give new hope to physicians and patients running low on options.

About Trofile

Trofile is a patient selection co-receptor tropism assay that determines which co-receptor a patient's HIV strain or strains use for viral entry- CCR5, CXCR4, or a combination of CCR5 and CXCR4. Which of these "cellular gateways" that a particular HIV strain uses to gain entry into a
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. XTL Provides Update on Phase I Clinical Trial of XTL-2125
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
6. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
7. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
8. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
9. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
10. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
11. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013 Oramed Pharmaceuticals Inc. ... drug delivery systems, announced today that the United States ... Investigational New Drug application(IND) for ORMD-0801, its oral insulin ... the FDA clearance to proceed," stated Nadav ... is a major milestone for Oramed and we look ...
(Date:5/16/2013)... NORTH CHICAGO, Ill. and MECHELEN, ... NV (Euronext: GLPG) and AbbVie (NYSE: ABBV ... development collaboration to include Crohn,s disease.  Galapagos will fund ... which is designed to facilitate rapid progression into Phase ... Q2 2015, AbbVie will pay Galapagos $50 million.  The ...
(Date:5/16/2013)... SYDNEY , May 16, 2013  HeartWare International, ... leading innovator of less invasive, miniaturized circulatory support technologies that ... that CEO Doug Godshall is scheduled ... 11:00 a.m. EDT on Monday, May 20, 2013.  The conference ... York Hotel. A live webcast of the Company,s ...
Breaking Medicine Technology:Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2
... , CARY, N.C., Nov. 20 Cornerstone Therapeutics Inc. ... on acquiring, developing and commercializing significant products primarily for ... had received a Warning Letter from the Food and ... tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg) ...
... , HARRISBURG, Pa., Nov. 20 The Department ... priority groups that did not have previous access to the vaccine. , ... Friday,s clinic hours are from 2 p.m. to 8 p.m. Hours on ... Nov. 22, the clinics will operate from 2 p.m. to 8 p.m. ...
Cached Medicine Technology:Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal 2Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal 3Pennsylvania Department of Health Begins Statewide H1N1 Vaccination Clinics Targeting Priority Populations; Some Appointments Still Available 2
(Date:5/18/2013)... California (PRWEB) May 18, 2013 Online watch ... be Rolex watch owners at a fraction of ... of luxury timepieces in the world, buyers are urged to ... compared to buying a Rolex watch from a brick-and-mortar store, ... owned Rolex watches priced at unbelievable rates. Although some ...
(Date:5/18/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay ... latest edition of what is considered the "bible" of ... changes continues. "This is unprecedented, the amount of ... president-elect of the American Psychiatric Association (APA). "It,s been ... is. You have to evaluate it and then make ...
(Date:5/18/2013)... a few extra cups of coffee each month might ... known as primary sclerosing cholangitis (PSC), a new study ... Minn., found that drinking coffee was associated with a ... to cirrhosis of the liver, liver failure and biliary ... relationship. "While rare, PSC has extremely detrimental ...
(Date:5/18/2013)... Orlando, FL (May 18, 2013) The use ... for a colonoscopy, according to new research presented ... process, which begins days in advance of the ... preparation medication to be taken at strict intervals. ... for doctors to see cancer and precancerous polyps ...
(Date:5/18/2013)... is associated with a reduced risk of primary ... Clinic research shows. The findings were being presented ... Orlando, Fla. , PSC is an inflammatory ... inflammation and subsequent fibrosis that can lead to ... cancer. , "While rare, PSC has extremely detrimental ...
Breaking Medicine News(10 mins):Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 2Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 2Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 4Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2Health News:New smartphone application improves colonoscopy preparation 2
... brain seen in people with Alzheimer's disease has been ... their cognitive abilities and become unusually forgetful. ,The ... who may develop Alzheimer's disease.Alzhiemer’s disease results in memory ... in the USA are estimated to suffer from this ...
... of Disease in Childhood recently published a study which proves ... hand-eye coordination of toddlers.// ,The trial was done ... fish oil/olive oil supplements from 20th week of their pregnancy ... and those who did not routinely eat more than two ...
... encephalopathy may need to get cooler at the top, to ... during birth. Such babies can now be helped with a ... damage. This product has been approved by the Food and ... device with the brand name of ‘Cool-Cap’ may be a ...
... the rules governing the private educational institutions in the ... ,The state cabinet decided to adopt the new rules ... an official said here. ,The school managements ... students, pay prescribed and timely salaries to teaching and ...
... study has indicated that inflammatory bowel disease in women could ... times.// , ,Diseases such as Crohn's disease and ulcerative ... babies or premature babies. Yet, the 'silver lining' exists in ... certainly reduced the risks. ,The St. Mary's ...
... January issue of the medical journal Otolaryngology- Head and Neck ... permanent long-term hearing loss that can be caused by exposure ... measured the impact of “impulse noise” (short bursts of acoustic ... by using short-term exposure to the impulse noise generated by ...
Cached Medicine News:Health News:Novel Brain Scan to Diagnose Alzheimer's Disease 2Health News:Novel Brain Scan to Diagnose Alzheimer's Disease 3Health News:Fish Oil Improves Toddler’s Hand-eye Coordinatio 2
Disposable tracheostomy care tray....
Disposable tracheostomy care tray....
... Has the Right Solution For Your Tracheostomy ... and care tray features the latest components ... important infection control task. Designed by clinicians, ... needs of each patient and caregiver. All ...
... Has the Right Solution For Your Tracheostomy ... and care tray features the latest components ... important infection control task. Designed by clinicians, ... needs of each patient and caregiver. All ...
Medicine Products: